These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 32737142)

  • 1. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141
    Pearson FE; Tullett KM; Leal-Rojas IM; Haigh OL; Masterman KA; Walpole C; Bridgeman JS; McLaren JE; Ladell K; Miners K; Llewellyn-Lacey S; Price DA; Tunger A; Schmitz M; Miles JJ; Lahoud MH; Radford KJ
    Clin Transl Immunology; 2020; 9(6):e1141. PubMed ID: 32547743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
    Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
    Front Immunol; 2020; 11():2043. PubMed ID: 32973811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
    Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CLEC9A delivers antigen to human CD141
    Tullett KM; Leal Rojas IM; Minoda Y; Tan PS; Zhang JG; Smith C; Khanna R; Shortman K; Caminschi I; Lahoud MH; Radford KJ
    JCI Insight; 2016 May; 1(7):e87102. PubMed ID: 27699265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.
    Yan Z; Wu Y; Du J; Li G; Wang S; Cao W; Zhou X; Wu C; Zhang D; Jing X; Li Y; Wang H; Gao Y; Qi Y
    Oncotarget; 2016 Jun; 7(26):40437-40450. PubMed ID: 27250027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
    Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
    Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
    Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
    Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
    Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
    Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.
    Lahoud MH; Radford KJ
    Hum Vaccin Immunother; 2022 Dec; 18(1):1873056. PubMed ID: 33625943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
    Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
    J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.
    Le Gall C; Cammarata A; de Haas L; Ramos-Tomillero I; Cuenca-Escalona J; Schouren K; Wijfjes Z; Becker AMD; Bödder J; Dölen Y; de Vries IJM; Figdor CG; Flórez-Grau G; Verdoes M
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35428705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
    Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
    Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.